|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0009324,
umls-concept:C0039225,
umls-concept:C0087111,
umls-concept:C0127615,
umls-concept:C0205177,
umls-concept:C0308355,
umls-concept:C0439416,
umls-concept:C0442027,
umls-concept:C1881878,
umls-concept:C1962987
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2005-11-10
|
|
pubmed:abstractText |
Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis. Additionally, Asacol dosed at 2.4 g/day has been proved to be more effective than 1.6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2478-85
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16279903-Administration, Oral,
pubmed-meshheading:16279903-Adolescent,
pubmed-meshheading:16279903-Adult,
pubmed-meshheading:16279903-Aged,
pubmed-meshheading:16279903-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:16279903-Colitis, Ulcerative,
pubmed-meshheading:16279903-Delayed-Action Preparations,
pubmed-meshheading:16279903-Double-Blind Method,
pubmed-meshheading:16279903-Female,
pubmed-meshheading:16279903-Follow-Up Studies,
pubmed-meshheading:16279903-Humans,
pubmed-meshheading:16279903-Male,
pubmed-meshheading:16279903-Mesalamine,
pubmed-meshheading:16279903-Middle Aged,
pubmed-meshheading:16279903-Placebos,
pubmed-meshheading:16279903-Recurrence,
pubmed-meshheading:16279903-Remission Induction,
pubmed-meshheading:16279903-Safety,
pubmed-meshheading:16279903-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
|
pubmed:affiliation |
Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
